Evidence map›Paper›PMID 39475454›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Artificial Microglia Nanoplatform Loaded With Anti-RGMa in Acoustic/Magnetic Feld for Recanalization and Neuroprotection in Acute Ischemic Stroke.

Ruiqi Cheng, Xiaoqin Luo, Xiaohui Wu, Zijie Wang, Ziqun Chen, Shaoru Zhang, Hongmei Xiao, Jiaju Zhong, Rongrong Zhang, Yang Cao and 1 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ruiqi ChengDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Xiaoqin LuoDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Xiaohui WuDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Zijie WangDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Ziqun ChenChongqing Key Laboratory of Ultrasound Molecular Imaging, Institute of Ultrasound Imaging, Ultrasound Department of the Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Shaoru ZhangDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Hongmei XiaoDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Jiaju ZhongDepartment of Rehabilitation Medicine, Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
Rongrong ZhangDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Yang CaoChongqing Key Laboratory of Ultrasound Molecular Imaging, Institute of Ultrasound Imaging, Ultrasound Department of the Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Xinyue QinDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.ORCID 0000-0002-4996-499X

Funding

Fund of Mountaintop Plan Project in the First Affiliated Hospital of Chongqing Medical University cyyy-xkdfjh-jcyj-202309National Natural Science Foundation of China 82071338National Natural Science Foundation of China 82101375Natural Science Foundation of Chongqing, China CSTB2022NSCQ-MSX0072The Science and Technology Research Program of Chongqing Municipal Education Commission KJZD-K202300409Young Outstanding Foundation of The First Affiliated Hospital of Chongqing Medical University ZYRC2020-02
6 · The paper itself

Abstract

Ischemic stroke is a leading cause of death and disability worldwide, and the main goals of stroke treatment are to destroy the thrombus to recanalize blood vessels and protect tissue from ischemia/reperfusion injury. However, current recanalization therapies have serious limitations and there are few neuroprotection methods. Hence, an artificial nanoplatform loaded with anti-Repulsive Guidance Molecule a monoclonal antibody (anti-RGMa) and coated with microglia membrane (MiCM) is reported for stroke treatment, namely MiCM@PLGA/anti-RGMa/Fe

Indexed as

Disease Models, AnimalIschemic StrokeMicrogliaAnimalsAntibodies, MonoclonalMaleMiceNanoparticlesNeuroprotectionAntibodies, Monoclonalischemic strokemicroglia membranenanoplatformneuroprotectionrecanalization

Identifiers

PMID39475454
PMCPMC11672321

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.